Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLEGRA ALLERGY vs ALLEGRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Relief of symptoms associated with seasonal allergic rhinitis (sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes),Treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (pruritus and hives)
Seasonal allergic rhinitis,Chronic idiopathic urticaria
Fexofenadine 180 mg orally once daily.
60 mg orally twice daily or 180 mg orally once daily.
Terminal elimination half-life is 14.4 hours (range 8–16 hours) in healthy adults. In renal impairment, half-life may be prolonged; dose adjustment recommended for Cr Cl <30 m L/min.
Terminal elimination half-life is approximately 14.4 hours in healthy adults, allowing for twice-daily dosing. In patients with renal impairment, half-life may be prolonged (up to 59 hours in severe impairment).
Fexofenadine undergoes minimal hepatic metabolism; approximately 5% of the dose is metabolized by CYP3A4. It is primarily excreted unchanged in feces and urine.
Minimally metabolized; undergoes hepatic metabolism via CYP3A4 to a lesser extent; mainly excreted unchanged in feces and urine.
Primarily eliminated in feces (80%) and urine (approximately 15%) as unchanged drug. Biliary secretion contributes significantly.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) and urine (approximately 11%). Biliary excretion accounts for the majority of fecal elimination. Renal elimination is minimal due to extensive tubular reabsorption.
60-70% bound to plasma proteins (mainly albumin and α1-acid glycoprotein).
60-70% bound, primarily to albumin and alpha-1-acid glycoprotein.
Steady-state volume of distribution (Vdss) is 5.4–16 L/kg (mean ~12 L/kg). The large Vd indicates extensive tissue distribution.
Vd is 5.4-6.7 L/kg, indicating extensive extravascular distribution. This large Vd reflects wide tissue penetration, though fexofenadine does not cross the blood-brain barrier significantly.
Oral bioavailability is approximately 30% (range 25–40%) due to first-pass metabolism. Bioavailability is reduced by fruit juices (e.g., grapefruit, apple, orange).
Oral bioavailability is approximately 33% (range 20-50%), with food reducing absorption by up to 20%. The absolute bioavailability is low due to first-pass metabolism and efflux transport (P-glycoprotein).
GFR 40-59 m L/min: 60 mg once daily; GFR 15-39 m L/min: 60 mg every other day; GFR <15 m L/min: not recommended.
For GFR < 30 m L/min: 60 mg orally once daily.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Insufficient data for severe (Child-Pugh C).
No adjustment required for hepatic impairment.
Children 2-11 years: 30 mg orally twice daily; Children 12 years and older: same as adult dosing.
Children 6-11 years: 30 mg orally twice daily; Children ≥12 years: same as adult.
No specific dose adjustment, but elderly patients may be more sensitive to anticholinergic effects; consider starting at lower end of dosing range. No renal adjustment needed if renal function normal.
No specific adjustment; use with caution due to potential renal impairment.
None.
None
Use with caution in patients with renal impairment (Cr Cl < 80 m L/min) as exposure is increased; consider dose adjustment.,Avoid concurrent use with aluminum- and magnesium-containing antacids, which reduce fexofenadine absorption by up to 40%.,Potential for QT prolongation at high doses (rare); caution in patients with pre-existing QT prolongation or electrolyte imbalances.,Not recommended for severe hepatic impairment due to lack of data.
Renal impairment: reduce dose in patients with Cr Cl < 80 m L/min; avoid use with known hypersensitivity; caution in patients with hepatic impairment.
Hypersensitivity to fexofenadine or any component of the formulation,End-stage renal disease (ESRD) with Cr Cl < 15 m L/min (use not recommended)
Hypersensitivity to fexofenadine or any component of the formulation; severe renal impairment (Cr Cl < 30 m L/min) for the tablet formulation.
Fruit juices (apple, orange, grapefruit) significantly decrease absorption of fexofenadine; avoid concurrent consumption. No other significant food interactions.
Fruit juices (apple, orange, grapefruit) reduce fexofenadine absorption by up to 36%, 36%, and 20% respectively; avoid concomitant intake within 4 hours; food does not significantly affect absorption, but administration with high-fat meal may slightly delay absorption; no specific food restrictions beyond fruit juice timing.
Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate, well-controlled studies in pregnant women. First trimester: Limited data suggest no increased risk of major malformations. Second and third trimesters: No known specific fetal risks from antihistamine use; however, use only if clearly needed due to lack of extensive human data.
Fexofenadine (ALLEGRA) is classified as FDA Pregnancy Category C. Animal studies in rats and rabbits at doses up to 3 and 7 times the maximum recommended human dose (MRHD) respectively showed no evidence of teratogenicity. However, there are no adequate and well-controlled studies in pregnant women. First trimester: Limited human data; theoretical risk based on lack of data. Second and third trimesters: No known specific fetal risks; antihistamines in late pregnancy may cause uterine irritability and neonatal withdrawal symptoms (tremors, irritability) if used near term. Overall, risk is considered low but not zero.
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.24. Based on limited data, the relative infant dose is estimated to be less than 5% of the maternal weight-adjusted dose, which is considered low. However, caution is advised due to potential effects on the infant, such as drowsiness or irritability. Use only if clearly needed, and monitor the infant for adverse effects.
Fexofenadine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 1.0. Based on a study, an exclusively breastfed infant would receive a dose of about 0.45% of the maternal weight-adjusted dose, which is considered negligible. No adverse effects have been reported in breastfed infants. The American Academy of Pediatrics considers fexofenadine compatible with breastfeeding. However, caution is advised for premature infants or those with renal impairment.
No specific dosing adjustments are recommended for fexofenadine during pregnancy, as pharmacokinetic data are limited. However, due to physiological changes in pregnancy (e.g., increased plasma volume, renal clearance), the standard adult dose (60 mg twice daily or 180 mg once daily) may require cautious use; consider lowest effective dose. No formal studies have been conducted to determine dose modifications.
No specific dose adjustments are recommended during pregnancy due to minimal changes in pharmacokinetics. However, pregnancy can increase volume of distribution and renal blood flow, but studies show that fexofenadine exposure (AUC) is similar between pregnant and non-pregnant women. Dosing remains 60 mg twice daily or 180 mg once daily for seasonal allergies. For patients with renal impairment (creatinine clearance <80 m L/min), reduce starting dose to 60 mg once daily regardless of pregnancy status.
Fexofenadine is a second-generation antihistamine with minimal CNS penetration, causing less sedation than first-generation agents. Onset of action is within 1 hour; peak effect at 2-3 hours. Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) due to reduced clearance. Antacids containing aluminum or magnesium reduce absorption; separate by at least 2 hours. No significant QT prolongation at therapeutic doses.
ALLEGRA (fexofenadine) is a non-sedating antihistamine; avoid co-administration with fruit juices (apple, orange, grapefruit) as they reduce absorption; onset within 1 hour, duration 12-24 hours; dose adjustment needed in renal impairment (Cr Cl <80 m L/min): start 60 mg once daily; not significantly metabolized by CYP450, low drug interaction potential; acts as a P-glycoprotein substrate.
Take with water; do not take with fruit juices (apple, orange, grapefruit) as they reduce absorption.,Do not use with antacids containing aluminum or magnesium; wait at least 2 hours between doses.,May cause mild drowsiness in some patients; avoid driving if affected.,Do not exceed recommended dose; overdose may cause dizziness, drowsiness, or dry mouth.,Store at room temperature away from moisture and heat.,Consult healthcare provider if symptoms persist >7 days or if fever occurs.
Take on an empty stomach with water for best absorption.,Do not take with fruit juices (apple, orange, grapefruit) as they decrease effectiveness.,May cause drowsiness in rare cases; avoid driving if affected.,Use consistently for best symptom control; do not exceed recommended dose.,If you have kidney disease, consult your doctor before use.
No interactions on record
No interactions on record
Common clinical questions about ALLEGRA ALLERGY vs ALLEGRA, answered by our medical review team.
ALLEGRA ALLERGY is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine-induced vasodilation and bronchoconstriction by blocking the H1 receptor, thereby reducing allergic symptoms.. ALLEGRA is a Antihistamine (Nonsedating) that works by Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLEGRA ALLERGY and ALLEGRA depend on the specific clinical indication. These are both Antihistamine (Nonsedating) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLEGRA ALLERGY is: Fexofenadine 180 mg orally once daily.. The standard adult dose of ALLEGRA is: 60 mg orally twice daily or 180 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLEGRA ALLERGY and ALLEGRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLEGRA ALLERGY is classified as Category C. Fexofenadine (ALLEGRA ALLERGY) is classified as FDA Pregnancy Category C. Animal studies have shown no teratogenicity at doses up to 2-3 times the human dose. There are no adequate. ALLEGRA is classified as Category C. Fexofenadine (ALLEGRA) is classified as FDA Pregnancy Category C. Animal studies in rats and rabbits at doses up to 3 and 7 times the maximum recommended human dose (MRHD) respecti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.